Presentation is loading. Please wait.

Presentation is loading. Please wait.

In Vitro Market 2013 Market Analysis.

Similar presentations

Presentation on theme: "In Vitro Market 2013 Market Analysis."— Presentation transcript:

1 In Vitro Market 2013 Market Analysis

2 Historical Trends 2013 Market Analysis

3 Historical Information
In Vitro, of Latin origin, literally means “in glass” due to the initial administration of drugs and biological specimens via a small glass tube. In Vitro takes place in a test tube, culture dish, or elsewhere outside of a living organism. Source:

4 Historical Information
Common examples of in vitro experiments include work that uses: Cells derived from multicellular organisms (cell culture or tissue culture) Subcellular components (e.g. mitochondria or ribosomes) Cellular or subcellular extracts (e.g. wheat germ or reticulocyte extracts) Purified molecules in the test tube (often proteins, DNA, or RNA, either individually or in combination). Source:

5 Historical Information
Living organisms are extremely complex functional systems that are made up of, at a minimum, many tens of thousands of genes, protein molecules, RNA molecules, small organic compounds, inorganic ions and complexes in an environment that is spatially organized by membranes and, in the case of multicellular organisms, organ systems Source:

6 Historical Information
In short, living organisms are very complex, but In Vitro allows simplicity.

7 Advantages and Disadvantages of In Vitro
2013 Market Analysis

8 Advantages of In Vitro Disadvantages of In Vitro The primary advantage of in vitro work is that it permits an enormous level of simplification of the system under study, so that the investigator can focus on a small number of components The primary disadvantage of in vitro is that it can sometimes be very challenging to extrapolate from the results of in vitro work back to the biology of the intact organism. Source:

9 Example of In Vitro Advantages
The identity of proteins of the immune system (e.g. antibodies), and the mechanism by which they recognize and bind to foreign antigens would remain very obscure if not for the extensive use of in vitro work to: Isolate the proteins Identify the cells and genes that produce them Study the physical properties of their interaction with antigens and Identify how those interactions lead to cellular signals that activate other components of the immune system. Source:

10 Examples of In Vitro Disadvantages
Scientists developing a new viral drug to treat an infection with a pathogenic virus (e.g. HIV-1) may find that a candidate drug functions to prevent viral replication in an in vitro setting (typically cell culture). However, before this drug is used in the clinic, it must progress through a series of in vivo trials to determine if it is safe and effective in intact organisms (typically small animals, primates and humans in succession). Typically, most candidate drugs that are effective in vitro prove to be ineffective in vivo because of issues associated with delivery of the drug to the affected tissues, toxicity towards essential parts of the organism that were not represented in the initial in vitro studies, or other issues. Source:

11 Examples of In Vitro testing and uses
2013 Market Analysis

12 Examples of In Vitro testing and uses
Polymerase chain reaction is a method for selective replication of specific DNA and RNA sequences in the test tube. Source:

13 Examples of In Vitro testing and uses
Protein purification involves the isolation of a specific protein of interest from a complex mixture of proteins, often obtained from homogenized cells or tissues. Source:

14 Examples of In Vitro testing and uses
In vitro fertilization is used to allow spermatozoa to fertilize eggs in a culture dish before implanting the resulting embryo or embryos into the uterus of the prospective mother. Source:

15 Examples of In Vitro testing and uses
In vitro diagnostics refers to a wide range of medical and veterinary laboratory tests that are used to diagnose diseases and monitor the clinical status of patients using samples of blood, cells or other tissues obtained from a patient. Source:

16 Worldwide players 2013 Market Analysis Source:

17 Worldwide Players Bio-Rad Laboratories Source:

18 Worldwide Players Bio-Rad Founded in 1952 in Berkley, California
Manufacturer and supplier of: Life science research Healthcare Analytical chemistry Other markets with products and systems used to separate complex chemical and biological materials and to identify, analyze, and purify their components Source:

19 Worldwide Players Bio-Rad operates in six industry segments:
Life Science Research Clinical Diagnostics Process Separations Food Science Spectroscopy Life Science Education Source:

20 Worldwide Players All segments operate worldwide.
Bio-Rad’s customers include: Hospitals Universities Major research institutions Biotechnology Pharmaceutical companies Secondary and tertiary academic institutions Source:

21 Worldwide Players Bio-Rad is the number one specialty diagnostics company in the world. The Clinical Diagnostics Group develops, manufactures, sells and supports a large portfolio of products for medical screening and diagnostics. Source:

22 Worldwide Players Bio-Rad holds leadership positions in diabetes monitoring and quality control (QC) systems. Bio-Rad is well known for: Blood virus testing and detection Blood typing Autoimmune and genetic disorders testing Internet-based software products. Source:

23 Worldwide Players Bio-Rad's Clinical Diagnostics segment encompasses a broad array of technologies incorporated into a variety of products used to detect, identify, monitor, and quantify substances in patient and donor blood, other bodily fluids, and tissue samples. The vast majority of these tests are performed in vitro (outside the body) Source:

24 Worldwide Players The market is split into several sub- segments consisting of: Clinical chemistry Immunoassay Microbiology Hematology Molecular Coagulation Blood banking Blood typing Source:

25 Worldwide Players Bio-Rad has significant positions in:
Blood virus testing (blood banking and immunoassay) Immunohematology (blood typing) Hemoglobin A1c testing for diabetes monitoring (clinical chemistry and immunoassay) Autoimmune disease testing (immunoassay) Quality control (crossing all sub-segments). Source:

26 Worldwide Players One medically significant product is Bio-Rad’s rapid dengue test, called the NS1 antigen test, which allows for dengue detection the first day of fever, rather than when antibodies rise some five or more days later. Source:

27 Worldwide Players Beckman Coulter Source:

28 Worldwide Players Beckman Coulter
Founded in 1935 as National Technical Laboratories to commercialize a pH meter Headquarters in Brea, California. Locations worldwide: Americas Europe Africa Middle East Pacific Asia Source:

29 Worldwide Players Beckman Coulter
Develops, manufactures, and markets products that simplify, automate and innovate complex biomedical testing. Beckman Coulter diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Life science research instruments are used to study complex biological problems including causes of disease and potential new therapies or drugs. Source:

30 Worldwide Players Beckman Coulter’s core customers:
Core clinical diagnostic customers are: Hospital laboratories Core life science customers are: Pharmaceutical and biotechnology companies Universities Medical schools Research institutions. Source:

31 Worldwide Players Beckman Coulter Analytical Machines
An-50 Ti and An-60 Ti Rotors An-50 TI Analytical rotor with an eight-place titanium rotor (painted black), rated for 50,000 RPM. Seven holes are for sample cells and the eighth is for the counterbalance; all are parallel to the axis of rotation. An-60 Ti Analytical rotor with a four-place titanium rotor (painted black), rated for 60,000 RPM. Three holes are for sample cells and the fourth is for the counterbalance; all are parallel to the axis of rotation. Source:

32 Worldwide Players Both rotors’ cell holes are numbered for easy identification, together with the windows in the cells, allow light to pass through the cells for analysis of the material being processed. A handle is attached for easy lifting of the rotor. Source:

33 Worldwide Players For over-speed protection, a photoelectric detector in the XL-A/XL-I system monitors the over-speed disk on the bottom of the rotor and shuts down the run if speeds exceeding the rotor’s rated maximum are detected. Magnets have been inserted in the over- speed disk between cell holes 1 and 4 (An-60 Ti) or 1 and 8 (An-50 Ti). A sensor in the rotor chamber, triggered by these magnets, is used for timing the light sources Source:

34 Worldwide Players AKSA Medical Source:

35 Worldwide Players AKSA Medical Located in the Netherlands
An independent distributor in the Benelux. Product range of AKSA Medical consists of the following product groups: Clinical Chemistry Immunochemistry Drugs of Abuse Hematology Microbiology / Virology Point of Care Testing (POCT) HPLC and LCMS/MS reagents, controls, calibrators Source:

36 Worldwide Players Aska Products: General Diagnostic Assays
Infectious Diseases Life Sciences Point of care Testing (POCT) Quality Control QC software Laboratory Instruments Reagents Special products Lipoprint HPLC LC-MS/MS Applications Happy Cell / 3D Cell Culture in HCS & HTS Toxicologie Source:

37 Worldwide Players AKSA has 19 suppliers, all of which are displayed below Randox Quantimetrix Corporation CisBiotech IVD Technologies LTA S.R.L RECIPE Chemical + Instruments GmbH Sentinel Diagnostics DiaMetra Express Diagnostics HIMedia Laboratories BioGroup Medical System Pilots Point BIOCRATES Biocroi Ltd. Boditech Princeton BioMitech Corporation IVD Research Inc. ACCESS BIO, Inc. LifeSign Source:

38 Future prospects and growth
2013 Market Analysis- European market Source:

39 European Sector It is anticipated that the IVD market in Western Europe will grow at a rate of 5% per annum. Germany has the biggest market share with sales of almost Euro 1.6 billion, accounting for 24% of the total European market. Italy has the next highest sales with revenues of Euro 1.1 billion and 18% of the market. After Italy come France, Spain, United Kingdom, Belgium and Switzerland. Source:

40 European Sector Market share in percentages Revenue growth in billions

41 European Sector The global IVD market is worth an estimated EUR 19.5 billion, broken down as follows: European sector (numbers in millions) Clinical Chemistry- 5,271 Infectious Diseases- 5,627 Rapid Tests Coagulation Endocrine Testing Glucose- 4,209 Haematology- 1,253 Blood Grouping/Typing Source:

42 European Sector The largest IVD segments are: Infectious diseases
Clinical chemistry Glucose Glucose and rapid tests are the fastest growing tests in the European sector. Source: The largest IVD segments are infectious diseases, clinical chemistry and glucose. Glucose and rapid tests are the fastest growing.

43 Future prospects and growth
2013 Market Analysis- China and India Source:

44 China and India The IVD markets of China and India, two countries that account for roughly one-third of the world’s population, have demonstrated remarkable growth during the past 15 years. The IVD markets have seen steady growth rates: 10-20% per year during the past 15 years Growth in India is starting from a substantially lower point. Pace of growth for both countries has increased China 25% growth India 18% growth Source:

45 China and India Increased prosperity and urbanization in both countries are allowing for a rapid increase of IVD use. Source:

46 China and India McEvoy & Farmer’s 2011 report on China’s IVD market estimates the size of the market to be $2.1 billion with a growth rate of about 25% Source:

47 China and India McEvoy & Farmer’s 2011 report on India’s IVD market estimates the market size to be $531 million and growing at approximately 18% Source:

48 Future Prospects and Growth
2013 Market Analysis- US Market Source:

49 Future Prospects and Growth
Causes of significant market growth: Introduction of the Patient Protection and Affordable Care Act (PPACA) in 2014 This will significantly affect the United States in vitro diagnostics (IVD) market landscape. Most notably, the implementation of this Act will increase the percentage of people covered by insurance, which will drive test volumes, especially as the US population ages and the demand for IVD increases. Source:

50 Future Prospects and Growth
Causes of significant market growth (cont..) The PPACA will also lead to increased centralization of IVD testing as more laboratories, hospitals and care facilities consolidate in the wake of health care reform. Although the rise of centralized labs will leave manufacturers with fewer potential sites for capital sales, these facilities will see high testing volumes and ultimately have the resources to purchase a broader array of diagnostic tests. Source:

51 Future Prospects and Growth
High testing volumes at centralized sites will mean that labs will look for vendors that can offer a broad range of instrumentation and automation equipment. Labs will prefer to purchase all of their equipment from one vendor to improve workflow logistics and reduce costs. Source:

52 Future Prospects and Growth
Overall results of growth: Majority of market share will be held by a few key multi-segment players, like: Siemens Healthcare Roche Abbott Laboratories Source:

53 Future Prospects and Growth
Large multinational companies will likely continue to dominate the market through 2017—especially those players with a finger in molecular diagnostics technologies. This market segment will grow rapidly through 2017, cannibalizing sales from more mature segments such as immunoassay and microbiology testing. Source:

54 Future Prospects and Growth
There is still uncertainty surrounding the PPACA and health care reform in the US. This has caused many facilities to delay purchasing IVD capital equipment Source:

55 Future Prospects and Growth
However, the increase in test volumes will outweigh these negative effects, and the US IVD market will see steady growth. Source:

56 Future Prospects and Growth
Overall growth projections of the In Vitro market: Nearly $8.6 Billion by 2017 in the U.S. Source: :

57 Conclusions 2013 In Vitro Market Analysis Source:

58 Conclusions The In Vitro diagnostic market is growing rapidly worldwide Rapid growth potential is certain virtually worldwide as developed countries readily use IVD testing As developing countries become westernized, the use of IVD testing will ensue as well. Source:

59 Conclusions It is vital to ensure that Asian and Pacific markets are not ignored as they are rapidly growing as leaders in the usage of IVD tests. Source:

Download ppt "In Vitro Market 2013 Market Analysis."

Similar presentations

Ads by Google